Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC. Small molecule drug discovery and development., oncology, biotechnology, melanoma, and colorectal cancer

69 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

544 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reducing the metabolic impact of modern meals, one meal at a time. SIGRID Therapeutics is a metabolic health company developing gut-local technologies designed to reduce the metabolic impact of modern meals. Powered by patented SiPore® technology, SIGRID products work locally in the gastrointestinal tract, where precisely engineered pores interact with digestive enzymes involved in carbohydrate and fat digestion. By slowing the breakdown of nutrients during digestion, SiPore® supports steadier post-meal patterns and improved metabolic stability over time. Our work is built on a simple idea: modern food environments deliver rapid metabolic load, creating repeated spikes and swings that place strain …

83 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Redefining the future of drug development with a non-conventional biopharmaceutical model Landmark BioVentures is an integrative corporate and drug development company using resources smartly to advance multiple innovative therapies. Anchored by foundational science, LBV uncovers hidden gems with unrealized therapeutic potential by connecting non-obvious dots and taking a strategically-focused active hands-on approach with each nexus company. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative deal-making in resource-constrained environments, to streamline drug development, focusing on holistic value creation and capture. drug development , …

120 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production …

33 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

365 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

135 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision Radiotherapy From Within BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose. radiotherapy, nuclear medicine, oncology, and medical devices

83 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details. Stem Cell Research, Biotechnology, and High Throughput Stemcell Research

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances -

421 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

419 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

448 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its …

257 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

173 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com. Nuclear Medicine & Nuclear Industry, Biotechnology, Pharmaceutical, …

54 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

728 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

673 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

491 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, Chemical process research, DMPK, and ADME

81 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

213 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

613 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

“Inspiring Minds Advancing Science” Life Sciences BC is a not-for-profit, non-government, industry association that supports and represents the life sciences community of British Columbia through leadership, facilitation of investment and partnering, advocacy, and promotion of our world-class science and industry. Biopharmaceuticals, Medical Devices, Medical Technologies, and Digital Health Care

347 similar entities Type: SMB Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

263 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

602 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

340 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

430 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Digital Therapeutic Company in Urology Devicare is a specialty biotech company dedicated to develop pathbreaking medical treatments in Urology combining the most recent scientific advances in nutritional therapy with digital technologies. Biotechnology, Medical devices , Digital Health , eHealth, Healthcare, and Digital Therapeutics

412 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

227 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

364 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

223 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Molecular Glues by Design TernaryTx, a pioneering biotech startup, with a revolutionary AI-driven platform for designing molecular glue therapeutics, opening new frontiers in drug discovery for previously "undruggable" targets.

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing novel medications for patients with atrial fibrillation InCarda Therapeutics is a clinical stage drug delivery company developinng novel drugs designed for rapid, safe, and effective cardioversion of atrial fibrillation (AF). AF afflicts over 10 million patients in the US alone and is growing rapidly. Cardiovascular, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Clinical Research, and Pre-Clinical Research

69 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

MindMed is now Definium Therapeutics, a rebrand that reflects our commitment to forging a new era of psychiatry by applying precision to psychedelic medicine. Follow our new page at the link below!

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Access. Better Lives. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Biopharmaceuticals, Research and Development, Biosimilars, Biotechnology, Pharmaceutical, Biogenerics, Health, Cell Line Development, Business Development, and Regulatory

240 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

573 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBio Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications.

168 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

212 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Making T-Cell Receptor Biologics a Reality T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. biotechnology, research, T cell, biologics, and science

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotech Company 100% Focused on Pediatric Cancer Drug Development A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

279 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Targeting Genetically Defined Cancers Beactica Therapeutics is a specialist drug discovery and development company, committed to the fight against cancer. Beactica is advancing a proprietary pipeline of first-in-class therapeutics by applying its molecular interaction-based drug discovery engine synergistically across multiple small molecule modalities – including allosteric modulators, protein–protein interaction inhibitors and targeted protein degraders (PROTACs). Surface Plasmon Resonance (SPR), Fragment-Based Drug Discovery, Interaction Analysis, Kinetics, Mechanism of action, Oncology, PROTACs, Allosteric Modulators, Therapeutics, and Drug Discovery

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

136 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing best-in-class NNMT inhibitors with a dual therapeutic effect to benefit patients with metabolic syndrome Cantoni Therapeutics is a biopharmaceutical spinout company from the University of Leiden (NL) developing best-in-class inhibitors of a single enzyme with a dual therapeutic effect to benefit patients with metabolic syndrome.

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing Breakthrough Cancer Immunotherapies Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. Cancer Immunotherapies, Phosphatases, Immuno-Oncology, Checkpoint inhibitors, CAR-T, and Solid tumours and Lymphomas

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing healthcare through innovative adenosine receptor-based drugs Palobiofarma S.L. is a Spanish biopharmaceutical company dedicated to discovering and developing innovative drugs based on the modulation of adenosine receptors.

254 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Targeted treatment of serious infections mycoBiologics is a University of Aberdeen biotech spinout company which is dedicated to developing new antibody therapies to improve the survival of patients suffering from life-threatening, drug-resistant infections. Antibody therapy, Anti-infectives, Antifungal, Antibacterial, and Drug discovery

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NEW FRONTIERS IN NEUROSCIENCE Neurentis PLC is a late-clinical stage UK specialty pharma company, focusing on neuroscience and specialising in the development of novel treatments for mental health and other neurological and psychiatric diseases. Our product pipeline is balanced with an advanced lead drug for the treatment of Treatment-Resistant Depression (TRD) in the last stages of drug development as well as earlier stage drug candidates in collaboration with research institutions and other companies. The company is run by experienced ex-pharma industry executives, with more than 35 years’ experience in the sector each. The company’s low-risk commercial strategy is to commercialize …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

290 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. …

132 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The Protein Design Company (TM) - new proteins and biochemistry for the production of valuable sustainable molecules Arzeda, The Protein Design CompanyTM, is a synthetic biology company that creates novel proteins, enzymes and specialty chemical products that compete on performance, cost and sustainability. Partnering with Fortune 500 companies, Arzeda has developed a portfolio of enzymes and specialty chemicals for polymers, pharmaceuticals, industrial chemicals and other advanced applications. More information at www.arzeda.com. Synthetic Biology, Bio-based Chemicals, and Protein Design

92 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

565 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Developing Innovative Cell Therapies Against Cancer Celyad Oncology is a biotechnology company focused on the discovery and development of tecnhlologies and platform for chimeric antigen receptor T cell (CAR T) therapies. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Immuno-Oncology, Cancer, Immnotherapy, shRNA multiplex, and CAR T-cells

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology